Related Experiment Video
Updated: Jul 3, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Lamotrigine for acute and chronic pain
1Churchill Hospital, Pain Research Unit, Old Road, Headington, Oxford, UK, OX3 7LJ. phil.wiffen@pru.ox.ac.uk
The Cochrane Database of Systematic Reviews
|April 20, 2007
Summary
Lamotrigine is not recommended for neuropathic pain due to limited evidence of effectiveness. This review found no significant benefits, with a notable risk of skin rash, suggesting other treatments are more suitable.
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Anticonvulsant medications are utilized for neuropathic pain management.
- This review evaluates lamotrigine's efficacy in pain relief.
Purpose of the Study:
- To assess the analgesic efficacy and adverse effects of lamotrigine for acute and chronic pain.
- To determine if lamotrigine is a viable treatment option for various pain conditions.
Main Methods:
- Systematic review of Randomized Controlled Trials (RCTs) identified through MEDLINE, EMBASE, and Cochrane Library.
- Included studies involved adults (18+) with acute or chronic pain, assessing pain intensity using validated scales.
- Meta-analysis was performed using fixed or random effects models based on statistical heterogeneity; Number-Needed-to-Treat (NNT) and Number-Needed-to-Harm (NNH) were calculated.
Main Results:
- Seven RCTs involving 502 participants with neuropathic pain were included; no studies on acute pain were found.
- Conditions studied included central post-stroke pain, diabetic neuropathy, HIV-related neuropathy, and trigeminal neuralgia.
- A statistically significant result was observed in one subgroup for HIV-related neuropathy, but it was deemed unlikely to be clinically significant (NNT 4.3). Approximately 7% of participants reported skin rash.
Conclusions:
- Lamotrigine is unlikely to be beneficial for treating neuropathic pain based on current limited evidence.
- More effective treatments, including other anticonvulsants and antidepressants, are available.
- Lamotrigine does not currently hold a significant therapeutic role for neuropathic pain management.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...